FreeCME

Emerging Approaches and Patient‐centered Care for Narcolepsy

CME: 1.0

Target Audience

The primary target audiences for the HCP activity are neurologists, sleep specialists, and specialty NPs and PAs. Secondary audiences include primary care physicians, internists, advanced practitioners, pharmacists, and nurses

Statement of Need/Program Overview

Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS), sleep paralysis, hypnagogic and hypnopompic hallucinations, disrupted nocturnal sleep, dysregulated rapid eye movement (REM) sleep, and cataplexy in most patients. Despite these obvious symptoms, narcolepsy is often under‐recognized, with diagnostic delays of up to 15 years, or misdiagnosed, depriving patients of appropriate treatment and care. However, if diagnosed accurately, emerging agents for narcolepsy could provide a new, patient‐centered management option.

Join a panel of expert clinicians and patient representatives for an in-depth discussion of the shifting standards of care for narcolepsy with or without cataplexy. Panelists will discuss strategies to address barriers to the recognition of the disorder and detail assessment tools and methods to ensure an accurate and timely diagnosis. In addition, the education will explore highly anticipated upcoming and more patient centered agents, indications, and classes of agents that are expected to further refine the narcolepsy treatment armamentarium.

Do you have patients who could benefit from related education on the recognition and care of narcolepsy? Direct your patients to MedLive.com to access the related patient-education activity, “More than Sleepiness: How Recognizing and Treating Narcolepsy Will Impact the Entire Family.”

Educational Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe signs and symptoms that support a suspicion of narcolepsy with/without cataplexy
  • Formulate a differential diagnosis for narcolepsy with/without cataplexy
  • Describe the adverse effects of EDS and interrupted sleep on patient QoL and overall health
  • Assess the safety, efficacy, and tolerability profiles of available and investigational therapies for the treatment of narcolepsy with/without cataplexy

Post a comment to this article